These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28646658)

  • 1. Investigation and structural elucidation of a new impurity in bulk drug of cilostazol by LC/MS/MS, FT-IR and NMR.
    Hu Z; Gao S; Gao J
    J Pharm Biomed Anal; 2017 Oct; 145():16-23. PubMed ID: 28646658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
    Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
    J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR.
    Raman B; Sharma BA; Butala R; Ghugare PD; Kumar A
    J Pharm Biomed Anal; 2010 May; 52(1):73-8. PubMed ID: 20079995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
    Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
    J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and identification of a major impurity in a new bulk drug candidate by preparative LC, ESI-MS(n), LC-MS-MS, and NMR.
    Li N; Yang J; Qin F; Li F; Gong P
    J Chromatogr Sci; 2007 Jan; 45(1):45-9. PubMed ID: 17254383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of new impurity in didanosine.
    Srinivasa Rao DV; Srinivas N; Bharathi Ch; Prasad ChS; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Nov; 45(3):516-20. PubMed ID: 17624711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impurity profile study of zaleplon.
    Bharathi Ch; Prabahar KJ; Prasad ChS; Kumar MS; Magesh S; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 May; 44(1):101-9. PubMed ID: 17367980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
    Raman B; Sharma BA; Mahale G; Singh D; Kumar A
    J Pharm Biomed Anal; 2011 Sep; 56(2):256-63. PubMed ID: 21664089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a new impurity in lisinopril.
    Shinde V; Trivedi A; Upadhayay PR; Gupta NL; Kanase DG; Chikate R
    J Pharm Biomed Anal; 2007 Jan; 43(1):381-6. PubMed ID: 16926080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116.
    Testen A; Plevnik M; Štefane B; Cigić IK
    Acta Pharm; 2019 Mar; 69(1):63-74. PubMed ID: 31259720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate.
    Bharathi Ch; Prabahar KJ; Prasad ChS; Srinivasa Rao M; Trinadhachary GN; Handa VK; Dandala R; Naidu A
    Pharmazie; 2008 Jan; 63(1):14-9. PubMed ID: 18271296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural identification and characterization of potential impurities of pantoprazole sodium.
    Reddy GM; Bhaskar BV; Reddy PP; Ashok S; Sudhakar P; Babu JM; Vyas K; Mukkanti K
    J Pharm Biomed Anal; 2007 Oct; 45(2):201-10. PubMed ID: 17629653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of potential impurities of rabeprazole sodium.
    Reddy GM; Bhaskar BV; Reddy PP; Sudhakar P; Babu JM; Vyas K; Reddy PR; Mukkanti K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1262-9. PubMed ID: 17134865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of thermal degradation impurity in brimonidine tartrate by HPLC, LC-MS/MS, and 2DNMR.
    Baksam V; Nimmakayala S; Devineni SR; Muchumarri RMR; Shandilya S; Kumar P
    J Pharm Biomed Anal; 2021 Oct; 205():114297. PubMed ID: 34391137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
    Gao T; Liu Y; Ji Y; Wu X; Xu J
    J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.